The domestic equity benchmarks ended lower on Friday, snapping a two-day winning streak. Selling pressure from foreign institutional investors (FIIs) and a strengthening US dollar weighed on investor ...

Indian shares closed lower on Friday after a choppy session. Markets gave up early gains as concerns about slowing earnings growth ...

The company's North American revenue has seen a decline of over 9%. One of the primary worries is the reduction in revenues ...

Motilal Oswal recommended Neutral rating on Dr Reddys Labs with a target price of Rs 1330 in its research report dated ...

Indian pharma companies like Dr Reddys, Zydus, Cipla, and Sun can sustain low double-digit EPS growth over the medium term.

Although Dr Reddy's Laboratories' Q3 earnings slightly exceeded analysts' expectations, the main point of concern was the ...

The generic drugmaker was the top loser on the Nifty Pharma index and the benchmark Nifty 50 index. "The drop in shares comes ...

Extending losses for the second session, Dr Reddy’s shares dropped 6.65% to hit a low of ₹1,203.60 on the BSE as investors weighed weak Q3 results.

Indian shares were subdued on Friday after U.S. President Donald Trump reiterated his firm stance on tariffs. At the World Economic ...

Dr Reddy's Laboratories share price plunged 6.66 per cent at Rs 1,203.50 per share on the NSE in Friday's intraday deals after analysts remained cautious on the company's Q3 performance ...

Revlimid is a medicine used to treat certain cancers and serious conditions affecting blood cells and bone marrow.

Dr Reddy’s shares tumbled up to 6% in early trade and at 9:46 am, they were trading 4.35% lower at Rs 1,233.25 on the Bombay Stock Exchange (BSE).